Ugurel, S., Fröhling, S., & Schadendorf, D. (2017). Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. European journal of cancer, 83, . https://doi.org/10.1016/j.ejca.2017.06.020
Chicago-Zitierstil (17. Ausg.)Ugurel, Selma, Stefan Fröhling, und Dirk Schadendorf. "Fulminant Response to Combined Checkpoint Inhibition with Ipilimumab Plus Nivolumab After Failure of Nivolumab Monotherapy in Metastatic Melanoma." European Journal of Cancer 83 (2017). https://doi.org/10.1016/j.ejca.2017.06.020.
MLA-Zitierstil (9. Ausg.)Ugurel, Selma, et al. "Fulminant Response to Combined Checkpoint Inhibition with Ipilimumab Plus Nivolumab After Failure of Nivolumab Monotherapy in Metastatic Melanoma." European Journal of Cancer, vol. 83, 2017, https://doi.org/10.1016/j.ejca.2017.06.020.